ITGAM and glioblastoma: Inhibition of this pathway in combination with anti-PD-L1 antibody treatment has been shown to reduce infiltration of blood-derived CD45high/CD11b+ macrophages and decrease PD-L1 protein expression in microglia, leading to improved survival in GBM-bearing mice resistant to TMZ37.